#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

CS

Diabetes a obezita - Issue 45/2023

3

Quo vadis, slovenská diabetológia?

9

The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus

Vladimír Uličiansky

18

Diabetes mellitus and options for early prevention of heart failure

Andrej Dukát, Peter Jackuliak, Juraj Payer

22

Evaluation of the current situation and possibilities in the management of obesity in Slovakia

Ubomíra Fábryová

29

Ceramides and cardiovascular disease

Ján Murín

34

Social services in diabetes mellitus

Andrea Bukovská

37

Practical experience with dapagliflozin: case reports

Viliam Vaník, Zbynek Schroner

43

The patient with type 2 diabetes is hemodynamically and metabolically stable, despite treatment, the progression of chronic kidney disease proceeds. What other options do we have? A case report

Zbynek Schroner

49

Empagliflozin in patients with chronic kidney disease: results of the EMPA-KIDNEY trial and implications for clinical practice

Peter Novodvorský

54

The head-to-head comparison of insulin glargine 300 units/ml and degludec 100 units/ml using the CGM technology: results of the InRange trial

Peter Novodvorský

61

New indication criteria: better availability of GLP1 receptor agonists for our patients

Zbynek Schroner

63

The SGLT2 inhibitor canagliflozin: benefits in the treatment of type 2 diabetes mellitus

Zbynek Schroner

66

Spomienka na MUDr. Blaženu Dyskovú

67

A glimpse into the 13th chamber – overt and covert manifestations of diabetes mellitus

Jozef Lacka

71

World Diabetes Congress, Lisabon 2022

Andrea Bukovská

73

Advanced Technologies & Treatments for Diabetes 2023, Berlín

Martin Haluzík

77

5th National SDS Symposium: How are we doing with technology in diabetology in Slovakia and what new things do we expect in the future?

Viera Doničová

Diabetes a obezita

Issue 45

2023 Issue 45

Most read in this issue

Journals

#ADS_BOTTOM_SCRIPTS#